Ask AI

Playing the Long Game: Improving Durable Control in IBD

Video
This activity is available for 1.00 CME/CE credit(s).

Released: September 01, 2026

Expiration: August 31, 2027

See Activity Collection

Explore practical strategies for helping patients with inflammatory bowel disease (IBD) achieve durable disease control, including patient-centered assessment and treat-to-target goals. Watch this on-demand webcast to review expert insights on the latest evidence for advanced therapies in IBD, long-term monitoring needs, and comorbidity management to optimize patient outcomes and quality of life.

Achieving control in IBD care

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with IBD do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 38-yr-old woman with ulcerative colitis has been receiving vedolizumab for 14 mo. CRP and fecal calprotectin are within target ranges. Recently, she reports stopping exercise due to fatigue. Her history is notable for obesity and hypertension. What is the most appropriate next step?

How confident are you in your answer?
4.

A 36-yr-old woman with moderate to severe ileal CD on adalimumab 40 mg Q2W, now 16 weeks pregnant, reports worsening abdominal pain and increased stool frequency. She has adequate therapeutic drug levels and no antibodies. Reassessment shows a CRP of 18 mg/L, fecal calprotectin of 520 mg/g, stool studies negative for infection, and intestinal ultrasound confirming ileal inflammation. What would you do next?​

How confident are you in your answer?
5.

A 29-yr-old woman with ileocolonic CD initially responded to anti-TNF therapy but lost response within 6 mo. She was subsequently switched to mirikizumab and achieved clinical remission, which has lasted for the last 6 mo. She asks if she can stop therapy. What would you do for this patient?

How confident are you in your answer?